IL28B polymorphism cannot predict response to interferon alpha treatment in patients with melanoma.

doi:10.1371/journal.pone.0112613

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

IL28B polymorphism cannot predict response to interferon alpha treatment in patients with melanoma.

PloS one - 1 Jan 2014

Probst Martin, Hoeller Christoph, Ferenci Peter, Staettermayer Albert F, Beinhardt Sandra, Pehamberger Hubert, Kittler Harald, Grabmeier-Pfistershammer Katharina

Abstract excerpt

BACKGROUND: Recent genome-wide association studies revealed the rs12979860 single nucleotide polymorphism (SNP) of the IL28B gene (CC genotype) to be the strongest pre-therapeutic predictor of therapy response to interferon alpha in patients with chronic hepatitis C infection. The favorable CC genotype is associated with significantly higher rates of sustained virologic response. No data exist on the role of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Disease Progression

Share to Interferon-alpha

Share to Interferons

Share to Interleukins

Share to Melanoma

Share to Pharmacogenetics

Share to Skin Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 25389973
DOI: 10.1371/journal.pone.0112613
PMCID: PMC4229256

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IL28B polymorphism cannot predict response to interferon alpha treatment in patients with melanoma.PMID 25389973Read ↗

IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-α.Semantic proximity Read ↗

Genetic variation in IL28B (IFNL3) and response to interferon-alpha treatment in myeloproliferative neoplasms.Semantic proximity Read ↗

Gene polymorphisms of interleukin-28, p21-activated protein kinases 4, and response to interferon-α based therapy in Chinese patients with chronic hepatitis B.Semantic proximity Read ↗

IL28B polymorphisms are not associated with the response to interferon-β in multiple sclerosis.Semantic proximity Read ↗

Influence of genetic variants in type I interferon genes on melanoma survival and therapy.Semantic proximity Read ↗

Interleukin-1β Gene (IL1B) rs1143634 (+3954 C>T) Polymorphism and Cutaneous Melanoma Risk: An Observational Case-Control Study in Northeast Italy.Semantic proximity Read ↗

Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial.Semantic proximity Read ↗

Association of cytokine gene polymorphisms with malignant melanoma in Caucasian population.Semantic proximity Read ↗

Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study.Semantic proximity Read ↗

Cytokine gene single nucleotide polymorphisms and susceptibility to and prognosis in cutaneous malignant melanoma.Semantic proximity Read ↗

The role of BRAF mutation in patients with high-risk malignant melanoma treated with high-dose adjuvant interferon therapy.Semantic proximity Read ↗

Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-α but Not Observation in Intermediate Risk Melanoma Patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.